These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 18154482

  • 1. New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.
    Zaffanello M, Franchini M, Fanos V.
    Pharmacotherapy; 2008 Jan; 28(1):125-30. PubMed ID: 18154482
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [Abstract] [Full Text] [Related]

  • 4. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA.
    Am J Cardiol; 2007 Aug 06; 100(3A):45J-52J. PubMed ID: 17666198
    [Abstract] [Full Text] [Related]

  • 5. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 06; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 6. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep 06; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 7. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
    Song JH, Cha SH, Hong SB, Kim DH.
    J Hypertens Suppl; 2006 Mar 06; 24(1):S101-6. PubMed ID: 16601562
    [Abstract] [Full Text] [Related]

  • 8. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R, Palmer BF.
    Am J Nephrol; 2008 Mar 06; 28(3):372-80. PubMed ID: 18073461
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov 06; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 10. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
    Cohn JN, Goldman JM.
    Am J Hypertens; 2008 Mar 06; 21(3):248-56. PubMed ID: 18219303
    [Abstract] [Full Text] [Related]

  • 11. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD.
    Rev Cardiovasc Med; 2007 Mar 06; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [Abstract] [Full Text] [Related]

  • 12. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Mar 06; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 13. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE.
    Am Heart J; 2000 Sep 06; 140(3):361-6. PubMed ID: 10966531
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ.
    Prev Cardiol; 2008 Sep 06; 11(4):215-22. PubMed ID: 19476574
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
    Ferrari P.
    Nephrology (Carlton); 2007 Feb 06; 12(1):81-9. PubMed ID: 17295666
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future.
    Mackenzie HS, Ziai F, Omer SA, Nadim MK, Taal MW.
    J Am Soc Nephrol; 1999 Apr 06; 10 Suppl 12():S283-6. PubMed ID: 10201884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.